Silexion Therapeutics Corp entered into an inducement offer letter agreement on September 28, 2026, with holders of 3,216,928 existing Series E warrants. These existing warrants were issued in a public offering completed on August 11, 2026, and were exercisable for ordinary shares at a price of $0.65 per share. Under the terms of the agreement, the holders agreed to exercise these warrants for cash at a reduced price of $0.2603 per share.
In exchange for the cash exercise, the Company agreed to issue new Series F and Series G warrants to the holders. These new warrants, collectively referred to as New Warrants, allow the purchase of up to 6,433,856 ordinary shares at an exercise price of $0.2603 per share. The Series F Warrants will expire five years after the effective date of the Resale Registration Statement, while the Series G Warrants will expire twenty-four months after that date.
The Company expects to receive aggregate gross proceeds of approximately $0.84 million from the exercise of the Existing Warrants, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co., LLC has been engaged as the exclusive placement agent and will receive a cash fee of 7.0% of the gross proceeds from the Existing Warrants and a management fee of 1.0% of the same proceeds. The Company also agreed to issue warrants to the Placement Agent or its designees to purchase up to 225,185 ordinary shares.
The closing of the transactions is expected to occur on or about September 29, 2026, subject to customary closing conditions. The Company intends to use the net proceeds from these transactions for general corporate purposes. The Company also agreed to file a registration statement on Form S-3 or another appropriate form within 30 days of the agreement to facilitate the resale of the New Warrant Shares.
